Thelansis

Methamphetamine Use Disorder Market Outlook Thelansis’s “Methamphetamine Use Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Methamphetamine Use Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the ...

Methamphetamine Use Disorder Market Outlook Thelansis’s “Methamphetamine Use Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Methamphetamine Use Disorder     treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Methamphetamine Use Disorder Overview Methamphetamine use disorder refers to the illicit use of methamphetamines as a drug of abuse. It is a cationic lipophilic molecule which stimulates the release and partially blocks the reuptake of newly synthesized catecholamines in the CNS (Cho and Melega, 2002). Due to its structural similarity, methamphetamine substitutes for the dopamine transporter (DAT), noradrenaline...

 Methamphetamine use disorder refers to the illicit use of methamphetamines as a drug of abuse. It is a cationic lipophilic molecule which stimulates the release and partially blocks the reuptake of newly synthesized catecholamines in the CNS (Cho and Melega, 2002). Due to its structural similarity, methamphetamine substitutes for the dopamine transporter (DAT), noradrenaline transporter (NET), serotonin transporter (SERT) and vesicular monoamine transporter-2 (VMAT-2) and reverses their endogenous function, thereby redistributing monoamines from storage vesicles into the cytosol. Further, most individuals admitted to treatment were non-Hispanic White (69%), followed by individuals of Mexican origin. ·        The rates of methamphetamine dependence appear to be roughly equivalent in men compared to women, with 53% of primary methamphetamine/amphetamine admissions being male.   Thelansis’s “Methamphetamine Use Disorder Market Outlook, Epidemi...

 Methamphetamine use disorder refers to the illicit use of methamphetamines as a drug of abuse. It is a cationic lipophilic molecule which stimulates the release and partially blocks the reuptake of newly synthesized catecholamines in the CNS (Cho and Melega, 2002). Due to its structural similarity, methamphetamine substitutes for the dopamine transporter (DAT), noradrenaline transporter (NET), serotonin transporter (SERT) and vesicular monoamine transporter-2 (VMAT-2) and reverses their endogenous function, thereby redistributing monoamines from storage vesicles into the cytosol. Further, most individuals admitted to treatment were non-Hispanic White (69%), followed by individuals of Mexican origin. ·        The rates of methamphetamine dependence appear to be roughly equivalent in men compared to women, with 53% of primary methamphetamine/amphetamine admissions being male. Thelansis’s “Methamphetamine Use Disorder Market Outlook, Epidemiology , C...

  Methamphetamine use disorder refers to the illicit use of methamphetamines as a drug of abuse. It is a cationic lipophilic molecule that stimulates the release, and partially blocks the reuptake, of newly synthesized catecholamines in the CNS (Cho and Melega, 2002). Due to its structural similarity, methamphetamine substitutes for the dopamine transporter (DAT), noradrenaline transporter (NET), serotonin transporter (SERT), and vesicular monoamine transporter-2 (VMAT-2) and reverses their endogenous function, thereby redistributing monoamines from storage vesicles into the cytosol. Further, the majority of individuals admitted to treatment were non-Hispanic White (69%), followed by individuals of Mexican origin.   Methamphetamine dependence is largely a disorder of the White population; however, this may be a byproduct of the regional variability in methamphetamine use, which is currently greatest in the West and parts of the Midwest. The rates of methamphetamine depen...